Vorinostat downregulates CD30 and decreases brentuximab vedotin efficacy in human lymphocytes. (Q38947524)

From Wikidata

Revision as of 11:32, 10 October 2018 by QuickStatementsBot (talk | contribs) (‎Removed claim: author name string (P2093): Zainul S Hasanali, #quickstatements; #temporary_batch_1535586924053; invoked by sourcemd_batch_processing on behalf of User:Daniel Mietchen (batch 13))

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

scientific article published on 15 October 2014

Language	Label	Description	Also known as
English	Vorinostat downregulates CD30 and decreases brentuximab vedotin efficacy in human lymphocytes.	scientific article published on 15 October 2014

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

Vorinostat downregulates CD30 and decreases brentuximab vedotin efficacy in human lymphocytes. (English)

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

author name string

Elliot M Epner

2

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

David J Feith

3

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

Thomas P Loughran

4

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

Clare E Sample

5

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

publication date

15 October 2014

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

Molecular Cancer Therapeutics

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

13

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

12

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

2784-2792

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

Antibody-drug conjugate (ADC) clinical pipeline: a review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258453

9 September 2017

Brentuximab vedotin: a CD30-directed antibody-cytotoxic drug conjugate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258453

9 September 2017

Gemtuzumab ozogamicin: time to resurrect?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258453

9 September 2017

Management of cutaneous T cell lymphoma: new and emerging targets and treatment options

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258453

9 September 2017

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258453

9 September 2017

The CD30 gene promoter microsatellite binds transcription factor Yin Yang 1 (YY1) and shows genetic instability in anaplastic large cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258453

9 September 2017

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258453

9 September 2017

Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drug

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258453

9 September 2017

Cell membrane-specific epitopes on CD30: Potentially superior targets for immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258453

9 September 2017

Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258453

9 September 2017

The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258453

9 September 2017

Regulation of transcription factor YY1 by acetylation and deacetylation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258453

9 September 2017

TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258453

14 September 2017

Selective induction of apoptosis by histone deacetylase inhibitor SAHA in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258453

14 September 2017

Characterization of a cell line, NKL, derived from an aggressive human natural killer cell leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258453

25 September 2017

Involvement of Sp1 and microsatellite repressor sequences in the transcriptional control of the human CD30 gene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258453

17 June 2018

A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin's lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258453

17 June 2018

Biochemical characterization and biosynthesis of the Ki-1 antigen in Hodgkin-derived and virus-transformed human B and T lymphoid cell lines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258453

17 June 2018

Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt's lymphoma cell line

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258453

17 June 2018

The epigenetics pipeline

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4258453

21 August 2018

Identifiers

10.1158/1535-7163.MCT-14-0593

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

7 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38947524&oldid=761363991"